These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 17093258)

  • 21. [Investigation and development of new drugs: from the molecule to drug].
    Marovac J
    Rev Med Chil; 2001 Jan; 129(1):99-106. PubMed ID: 11265215
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Trends in development and approval times for new therapeutics in the United States.
    Reichert JM
    Nat Rev Drug Discov; 2003 Sep; 2(9):695-702. PubMed ID: 12951576
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evidence of comparative efficacy should have a formal role in European drug approvals.
    Sorenson C; Naci H; Cylus J; Mossialos E
    BMJ; 2011 Sep; 343():d4849. PubMed ID: 21896610
    [No Abstract]   [Full Text] [Related]  

  • 24. Translation of cancer immunotherapies.
    Mulé JJ; Weber JS
    Nat Med; 2004 Nov; 10(11):1153; author reply 1153-4. PubMed ID: 15516900
    [No Abstract]   [Full Text] [Related]  

  • 25. SuperGenerics: a better alternative for biogenerics.
    Charles SA
    Drug Discov Today; 2005 Apr; 10(8):533-5. PubMed ID: 15837591
    [No Abstract]   [Full Text] [Related]  

  • 26. TransMolecular receives FDA approval for 131-I-TM-601 IND application.
    Expert Rev Anticancer Ther; 2002 Apr; 2(2):139. PubMed ID: 12113233
    [No Abstract]   [Full Text] [Related]  

  • 27. Assessing a structured, quantitative health outcomes approach to drug risk-benefit analysis.
    Garrison LP; Towse A; Bresnahan BW
    Health Aff (Millwood); 2007; 26(3):684-95. PubMed ID: 17485745
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Industry perspectives on ICH guidelines.
    Rockhold FW
    Stat Med; 2002 Oct; 21(19):2949-57. PubMed ID: 12325111
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Characteriation of clinical data packages using foreign data in new drug applications in Japan.
    Tanaka M; Nagata T
    Clin Pharmacol Ther; 2008 Sep; 84(3):340-6. PubMed ID: 17786162
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The experience with voluntary genomic data submissions at the FDA and a vision for the future of the voluntary data submission program.
    Orr MS; Goodsaid F; Amur S; Rudman A; Frueh FW
    Clin Pharmacol Ther; 2007 Feb; 81(2):294-7. PubMed ID: 17259954
    [TBL] [Abstract][Full Text] [Related]  

  • 31. New drug approval times and clinical evidence in Japan.
    Ono S; Yoshioka C; Asaka O; Tamura K; Shibata T; Saito K
    Contemp Clin Trials; 2005 Dec; 26(6):660-72. PubMed ID: 16122988
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The FDA's drug review process: ensuring drugs are safe and effective.
    Meadows M
    FDA Consum; 2002; 36(4):19-24. PubMed ID: 12184298
    [No Abstract]   [Full Text] [Related]  

  • 33. Drug safety on trial.
    Nature; 2005 Mar; 434(7033):545. PubMed ID: 15800579
    [No Abstract]   [Full Text] [Related]  

  • 34. Drug development process for a product with a primary pediatric indication.
    Allen AJ; Michelson D
    J Clin Psychiatry; 2002; 63 Suppl 12():44-9. PubMed ID: 12562061
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law.
    Dinh TQ
    Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027
    [No Abstract]   [Full Text] [Related]  

  • 36. Drug therapy in long term care: new drug options spur a focus on outcomes.
    Dewey J
    Provider; 1995 Jan; 21(1):44-6, 48, 50 passim. PubMed ID: 10139882
    [No Abstract]   [Full Text] [Related]  

  • 37. How FDA approves biotechnology drugs.
    Manuel SM; Piascik P
    Am Pharm; 1995 May; NS35(5):14-5. PubMed ID: 7611131
    [No Abstract]   [Full Text] [Related]  

  • 38. Support for trials of promising medications through the Pharmaceutical Benefits Scheme. A proposal for a new authority category.
    Glasziou PP
    Med J Aust; 1995 Jan; 162(1):33-6. PubMed ID: 7605432
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Controlling type I error rate for fast track drug development programmes.
    Shih WJ; Ouyang P; Quan H; Lin Y; Michiels B; Bijnens L
    Stat Med; 2003 Mar; 22(5):665-75. PubMed ID: 12587098
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The marketplace can't give us the drug safety data we need.
    Avorn J
    MedGenMed; 2007 Feb; 9(1):29. PubMed ID: 17435636
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.